Mast cells and cutaneous malignancies - PubMed (original) (raw)

Review

Mast cells and cutaneous malignancies

Sydney Ch'ng et al. Mod Pathol. 2006 Jan.

Free article

Abstract

This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Mast cells accumulate around cutaneous malignancies. Current evidence suggests that mast cells contribute to the tumorigenesis of cutaneous malignancies through four mechanisms. (1) Immunosuppression: Ultraviolet-B radiation, the most important initiator of cutaneous malignancies, activates mast cells. Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers. These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma. Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix. Mast cell proteases reorganize the stroma to facilitate endothelial cell migration. As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells. Current evidence supports an accessory role for mast cells in the development and progression of cutaneous malignancies. Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in tumor biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.

PubMed Disclaimer

Cited by

Immunotherapy in Basal Cell Carcinoma.
Ungureanu L, Vasilovici AF, Halmágyi SR, Trufin II, Apostu AP, Prisecaru M, Șenilă SC. Ungureanu L, et al. J Clin Med. 2024 Sep 26;13(19):5730. doi: 10.3390/jcm13195730. J Clin Med. 2024. PMID: 39407789 Free PMC article. Review.
Mast cell density in Merkel cell carcinoma and its correlation with prognostic features and MCPyV status: a pilot study.
Cazzato G, Tamma R, Fanelli M, Colagrande A, Marzullo A, Cascardi E, Trilli I, Lorusso L, Lettini T, Ingravallo G, Ribatti D. Cazzato G, et al. Clin Exp Med. 2024 Jul 5;24(1):151. doi: 10.1007/s10238-024-01366-4. Clin Exp Med. 2024. PMID: 38967728 Free PMC article.
Mast Cell: A Mysterious Character in Skin Cancer.
Alda S, Ceausu RA, Gaje PN, Raica M, Cosoroaba RM. Alda S, et al. In Vivo. 2024 Jan-Feb;38(1):58-68. doi: 10.21873/invivo.13410. In Vivo. 2024. PMID: 38148067 Free PMC article. Review.
Integrating scRNA-seq and bulk RNA-seq to characterize infiltrating cells in the colorectal cancer tumor microenvironment and construct molecular risk models.
Wang Q, Zhang YF, Li CL, Wang Y, Wu L, Wang XR, Huang T, Liu GL, Chen X, Yu Q, He PF. Wang Q, et al. Aging (Albany NY). 2023 Dec 5;15(23):13799-13821. doi: 10.18632/aging.205263. Epub 2023 Dec 5. Aging (Albany NY). 2023. PMID: 38054820 Free PMC article.
The Immune Microenvironment in Basal Cell Carcinoma.
Zilberg C, Lyons JG, Gupta R, Damian DL. Zilberg C, et al. Ann Dermatol. 2023 Aug;35(4):243-255. doi: 10.5021/ad.22.042. Ann Dermatol. 2023. PMID: 37550225 Free PMC article. Review.

Mast cells and cutaneous malignancies - PubMed (original) (raw)